Tocilizumab in the treatment of twelve cases with aa amyloidosis secondary to familial mediterranean fever

---

Copy For Citation

Ugurlu S., Hacioglu A., Adibnia Y., Hamuryudan V., Ozdogan H.

ORPHANET JOURNAL OF RARE DISEASES, vol.12, 2017 (SCI-Expanded)

• Publication Type: Article / Article
• Volume: 12
• Publication Date: 2017
• Doi Number: 10.1186/s13023-017-0642-0
• Journal Name: ORPHANET JOURNAL OF RARE DISEASES
• Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
• Istanbul University Affiliated: Yes

Abstract

Background: There is no established treatment of AA amyloidosis, a long-term complication of various chronic inflammatory diseases associated with increased mortality, such as familial Mediterranian fever (FMF). Recently there are few reports pointing out that tocilizumab(TCZ), an anti IL-6 agent may be effective in AA amyloidosis resistant to conventional treatments. We report our data on the effect of TCZ in patients with FMF complicated with AA amyloidosis.